📰 Greg Behar News
Page 2 - Greg Behar News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Greg Behar. Real-time updates on events, politics, business and more.
September 4, 2023
By Adria Calatayud Nestle said it has sold its Palforzia peanut-allergy treatment business to biopharmaceutical company Stallergenes Greer. The Swiss...
September 4, 2023
(RTTNews) - Swiss food and beverage giant Nestle SA (NSRGY.PK, NSTR.L) Monday said it has divested peanut allergy treatment business, Palforzia, t...
September 4, 2023
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français and Deutsch ............. Vevey, September 4, 2023 Nestlé divests its Palforzia business ...
September 4, 2023
Food giant Nestlé has divested Palforzia, its peanut allergy treatment business, to biopharmaceutical firm Stallergenes Greer.
September 4, 2023
Nestlé has offloaded Palforzia, its peanut allergy treatment business, to biopharmaceutical company Stallergenes Greer.
September 2, 2023
The latest treatment for peanut allergy can cost around $10,000 a year and was supposed to be a pharma blockbuster. What went wrong?
June 5, 2023
– VOWST is now available by prescription in the U.S. for adult patients following antibiotic treatment for recurrent CDI – – VOWST Voyage™ Support Program to help reduce... | June 5, 2023
April 26, 2023
It’s the first pill to treat a serious and sometimes fatal bacterial condition.
December 4, 2022
Nestle put its Palforzia peanut-allergy treatment up for sale only two years after buying it, as Chief Executive Officer Mark Schneider reverses course on one of his biggest acquisitions beyond the Swiss companys traditional food and beverage operations.
October 11, 2022
11.10.2022 - ChromaDex Corp. (NASDAQ:CDXC) (“the Company” or “ChromaDex”) a global bioscience company dedicated to healthy aging, announced today a new long term commercial license and supply agreement with Nestlé Health Science, a global leader in science-based ... Seite 1